PharmaCyte Biotech Inc
NASDAQ:PMCB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.63
1.81
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
PharmaCyte Biotech Inc
NASDAQ:PMCB
|
6.1m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
169B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.8B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
PharmaCyte Biotech Inc
Glance View
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Laguna Hills, California and currently employs 4 full-time employees. The company went IPO on 2003-09-11. The firm is focused on developing cellular therapies for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Cell-in-a-Box technology is used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). The firm's lead product candidate, CypCaps is in Phase II of the clinical trials in LAPC. The company also focused on developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The firm is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant, such as cannabinoids.